Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CSTL - Castle Biosciences Inc


IEX Last Trade
29.7
-0.090   -0.303%

Share volume: 239,041
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$29.79
-0.09
-0.30%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
0.34%
1 Month
25.03%
3 Months
22.55%
6 Months
21.65%
1 Year
49.02%
2 Year
1.02%
Key data
Stock price
$29.70
P/E Ratio 
-264.31
DAY RANGE
N/A - N/A
EPS 
-$0.11
52 WEEK RANGE
$12.07 - $30.50
52 WEEK CHANGE
$0.51
MARKET CAP 
819.105 M
YIELD 
N/A
SHARES OUTSTANDING 
27.607 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$374,476
AVERAGE 30 VOLUME 
$516,224
Company detail
CEO:
Region: US
Website: castlebiosciences.com
Employees: 441
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.

Recent news